Literature DB >> 20669972

Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Sandra C Mwakwari1, William Guerrant, Vishal Patil, Shabana I Khan, Babu L Tekwani, Zachary A Gurard-Levin, Milan Mrksich, Adegboyega K Oyelere.   

Abstract

Inhibition of histone deacetylase (HDAC) function is a validated therapeutic strategy for cancer treatment. Of the several structurally distinct small molecule histone deacetylase inhibitors (HDACi) reported, macrocyclic depsipeptides possess the most complex cap groups and have demonstrated excellent HDAC inhibition potency and isoform selectivity. Unfortunately, the development of macrocyclic depsipeptides has been hampered in part because of development problems characteristic of large peptides and the complex reaction schemes required for their synthesis. Herein we report that tricyclic ketolide TE-802 is an excellent mimetic for the peptide backbone of macrocyclic HDACi. Compounds derived from this template are particularly selective against HDACs 1 and 2 with nanomolar inhibitory activity. Interrogation of the association between a subset of these compounds and key HDAC isoforms, using AutoDock, enables a molecular description of the interaction between the HDAC enzyme's outer rim and the inhibitors' macrocyclic cap group that are responsible for compound affinity and presumably isoform selectivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20669972      PMCID: PMC2924451          DOI: 10.1021/jm100507q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  45 in total

1.  A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors.

Authors:  William Guerrant; Sandra C Mwakwari; Po C Chen; Shabana I Khan; Babu L Tekwani; Adegboyega K Oyelere
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

Review 2.  Histone deacetylase inhibitors.

Authors:  Thomas A Miller; David J Witter; Sandro Belvedere
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

3.  Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.

Authors:  W Gu; R G Roeder
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

4.  A method for connecting solution-phase enzyme activity assays with immobilized format analysis by mass spectrometry.

Authors:  Dal-Hee Min; Woon-Seok Yeo; Milan Mrksich
Journal:  Anal Chem       Date:  2004-07-15       Impact factor: 6.986

5.  Histone deacetylase inhibitors--a new tool to treat cancer.

Authors:  Raz Somech; Shai Izraeli; Amos J Simon
Journal:  Cancer Treat Rev       Date:  2004-08       Impact factor: 12.111

6.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.

Authors:  John R Somoza; Robert J Skene; Bradley A Katz; Clifford Mol; Joseph D Ho; Andy J Jennings; Christine Luong; Andrew Arvai; Joseph J Buggy; Ellen Chi; Jie Tang; Bi-Ching Sang; Erik Verner; Robert Wynands; Ellen M Leahy; Douglas R Dougan; Gyorgy Snell; Marc Navre; Mark W Knuth; Ronald V Swanson; Duncan E McRee; Leslie W Tari
Journal:  Structure       Date:  2004-07       Impact factor: 5.006

7.  Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.

Authors:  Xenia Beebe; Fan Yang; Mai H Bui; Michael J Mitten; Zhenkun Ma; Angela M Nilius; Stevan W Djuric
Journal:  Bioorg Med Chem Lett       Date:  2004-05-17       Impact factor: 2.823

8.  Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity.

Authors:  M T Makler; J M Ries; J A Williams; J E Bancroft; R C Piper; B L Gibbins; D J Hinrichs
Journal:  Am J Trop Med Hyg       Date:  1993-06       Impact factor: 2.345

9.  Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay.

Authors:  H Babich; E Borenfreund
Journal:  Appl Environ Microbiol       Date:  1991-07       Impact factor: 4.792

Review 10.  Targeted histone deacetylase inhibition for cancer therapy.

Authors:  D M Vigushin; R C Coombes
Journal:  Curr Cancer Drug Targets       Date:  2004-03       Impact factor: 3.428

View more
  19 in total

Review 1.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

3.  Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.

Authors:  C T Chan; J Qi; W Smith; R Paranol; R Mazitschek; N West; R Reeves; G Chiosis; S L Schreiber; J E Bradner; R Paulmurugan; S S Gambhir
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

4.  Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel.

Authors:  Arren Z Washington; Subhasish Tapadar; Alex George; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2015-05-06       Impact factor: 3.641

5.  3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.

Authors:  Vishal Patil; Quaovi H Sodji; James R Kornacki; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

6.  Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.

Authors:  Idris Raji; Kabir Ahluwalia; Adegboyega K Oyelere
Journal:  Bioorg Med Chem Lett       Date:  2017-01-17       Impact factor: 2.823

7.  Dual-acting histone deacetylase-topoisomerase I inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Li-Pan Yao; Rebecca Hood; Adegboyega K Oyelere
Journal:  Bioorg Med Chem Lett       Date:  2013-04-04       Impact factor: 2.823

Review 8.  Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes.

Authors:  Patrick M Lombardi; Kathryn E Cole; Daniel P Dowling; David W Christianson
Journal:  Curr Opin Struct Biol       Date:  2011-08-25       Impact factor: 6.809

Review 9.  Chemical metabolic inhibitors for the treatment of blood-borne cancers.

Authors:  Martin Villalba; Nuria Lopez-Royuela; Ewelina Krzywinska; Moeez G Rathore; Robert A Hipskind; Houda Haouas; Nerea Allende-Vega
Journal:  Anticancer Agents Med Chem       Date:  2014-02       Impact factor: 2.505

10.  Molecular architecture of zinc chelating small molecules that inhibit spliceosome assembly at an early stage.

Authors:  Vishal Patil; Josh C Canzoneri; Timur R Samatov; Reinhard Lührmann; Adegboyega K Oyelere
Journal:  RNA       Date:  2012-07-25       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.